Related references
Note: Only part of the references are listed.Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment
Bingkun Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides
Shuji Kojima et al.
DOSE-RESPONSE (2018)
One-step labelling of a novel small-molecule peptide with astatine-211: preliminary evaluation in vitro and in vivo
Weihao Liu et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2018)
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators
Jan Kozempel et al.
MOLECULES (2018)
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Mehran Makvandi et al.
TARGETED ONCOLOGY (2018)
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
Hossein Jadvar
AMERICAN JOURNAL OF ROENTGENOLOGY (2017)
Linear Peptides in Intracellular Applications
Cristiane R. Zuconelli et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Antitumor Effect of Nanoparticle 131I-Labeled Arginine-Glycine-Aspartate-Bovine Serum Albumin-Polycaprolactone in Lung Cancer
Hui Ming et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2017)
Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression
Wei Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
Yana Dekempeneer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
Damian J. Green et al.
BLOOD (2015)
Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts
S. Lucas et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2015)
90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts
Kentaro Fujiwara et al.
PLOS ONE (2015)
Sequential Radioimmunotherapy with 177Lu-and 211At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model
Sophie E. Eriksson et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Stabilization of Peptides for Intracellular Applications by Phosphoramidate-Linked Polyethylene Glycol Chains
Nicole Nischan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
Michel Cherel et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Screening of a Specific Peptide Binding to VPAC1 Receptor from a Phage Display Peptide Library
Bo Tang et al.
PLOS ONE (2013)
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after Lu-177-DOTA-Tyr(3)-octreotate treatment: a histological study in xenografted mice
Ann Erlandsson et al.
EJNMMI RESEARCH (2011)
Preparation and preliminary evaluation of 211At-labeled amidobisphophonates
Yuanyou Yang et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2010)
131I-Tositumomab (BexxarA®) vs. 90Y-Ibritumomab (ZevalinA®) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
Andrei Iagaru et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
Modified 90Y-hydroxyapatite microparticles, possible agent for lung cancer therapy
Nadezda Nikolic et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Radioimmunotherapy of Lymphoma: Bexxar and Zevalin
Stanley J. Goldsmith
SEMINARS IN NUCLEAR MEDICINE (2010)
Cancer Therapy with Alpha-Emitters Labeled Peptides
Ekaterina Dadachova
SEMINARS IN NUCLEAR MEDICINE (2010)
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jane N. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells
Ana Valdehita et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Preparation of Rh[16aneS4-diol]211At and Ir[16aneS4-diol]211At complexes as potential precursors for astatine radiopharmaceuticals.: Part I:: Synthesis
Marek Pruszynski et al.
BIOCONJUGATE CHEMISTRY (2008)
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213
Giovanni Lucignani
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Immunogenicity of iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients
Hui Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology
Marc Laburthe et al.
PEPTIDES (2007)
Fractionated radio immunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2:: therapeutic efficacy and myelotoxicity
Jorgen Elgqvist et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
High expression of peptide receptors as a novel target in gastrointestinal stromal tumours
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
